Renfu Pharmaceutical: Carboxymethyl starch oral solution obtains drug registration certificate.

Renfu Pharmaceuticals announced that its holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" for Carvedilol Oral Solution issued by the National Medical Products Administration. Carvedilol Oral Solution is used to treat patients with chronic bronchitis and other diseases that cause thick phlegm and difficulties in coughing up phlegm. Yichang Renfu submitted an application for market approval in July 2023 and has been accepted. As of now, the cumulative research and development investment for this project is approximately 7 million yuan. The national sales of Carvedilol Oral Solution in 2024 are expected to be around 670 million yuan. This approval marks the company's qualification to sell this drug in the Chinese market.